KORSUVA® IS A TARGETED, FIRST-IN-CLASS AND THE ONLY LICENSED TREATMENT FOR CKD-ASSOCIATED PRURITUS IN THE US, EU AND SINGAPORE*1,2
By activating kappa-opioid receptors (KORs), KORSUVA® addresses two underlying mechanisms of chronic kidney disease-associated pruritus (CKD-aP).2-4
- KORSUVA® is a small peptide, with a hydrophilic structure which restricts its diffusions across the blood-brain barrier, limiting access to KORs in the CNS1
- KORSUVA® is highly selective towards KORs (>30,000 fold over mu-opioid receptors (MORs)2
